Seo Yu Bin, Choi Yu Jung, Seo Jun-Won, Kim Eun Jung, Lee Jacob, Song Joon Young
Division of Infectious Disease, Department of Internal Medicine, Kangnam Sacred Heart Hospital, Hallym University College of Medicine, Seoul, Republic of Korea.
Division of Infectious Diseases, Department of Internal Medicine, Korea University College of Medicine, Seoul, Republic of Korea.
BMC Infect Dis. 2025 May 22;25(1):731. doi: 10.1186/s12879-025-11131-x.
This scoping review aimed to summarize the available studies to address the question of which therapeutic agents can be utilized for patients with post-acute sequelae of COVID-19 (PASC).
We conducted a systematic search in medical databases, including PubMed and Embase, for studies aligned with our objectives published between January 1, 2020, and July 22, 2024. For each study, we summarized the main symptoms targeted, study design, therapeutic regimens, evaluation tools, and clinical outcomes.
A total of 413 studies were identified, and 39 studies were included in this review based on relevance to the research objectives. We primarily focused on high-level evidence studies, such as meta-analyses and randomized controlled trials, but observational studies were included when evidence was scarce. Therapeutic agents evaluated included hyperbaric oxygen, ivermectin, metformin, naltrexone, micronutrient supplements, antifibrotic agents, antiviral agents, and selective serotonin reuptake inhibitors (SSRIs). Among these, hyperbaric oxygen, antifibrotic agents, antiviral agents, and SSRIs demonstrated promising results. However, the heterogeneity of PASC symptoms posed challenges in synthesizing findings for specific symptom-based outcomes.
Given the heterogeneity of symptoms, this review highlights the need for standardized and targeted research to better address the diverse therapeutic needs of patients with PASC.
Not applicable.
本综述旨在总结现有研究，以解决哪些治疗药物可用于新冠后遗症（PASC）患者的问题。
我们在包括PubMed和Embase在内的医学数据库中进行了系统检索，以查找2020年1月1日至2024年7月22日期间发表的与我们目标相符的研究。对于每项研究，我们总结了所针对的主要症状、研究设计、治疗方案、评估工具和临床结果。
共确定了413项研究，基于与研究目标的相关性，本综述纳入了39项研究。我们主要关注高级别证据研究，如荟萃分析和随机对照试验，但在证据稀缺时也纳入了观察性研究。评估的治疗药物包括高压氧、伊维菌素、二甲双胍、纳曲酮、微量营养素补充剂、抗纤维化药物、抗病毒药物和选择性5-羟色胺再摄取抑制剂（SSRI）。其中，高压氧、抗纤维化药物、抗病毒药物和SSRI显示出有前景的结果。然而，PASC症状的异质性给基于特定症状的结果综合研究结果带来了挑战。
鉴于症状的异质性，本综述强调需要进行标准化和有针对性的研究，以更好地满足PASC患者的多样化治疗需求。
不适用。
